First, Duque of the DOH said an inter-agency resolution of the task force required that Pfizer`s overview of its vaccines be given to the Department of Science and Technology-Philippine Council for Health Research and Development as the lead agency for vaccine evaluation. The pfizer and BioNTech vaccine was also the first to show promising results with 95% efficacy. This was announced on November 18. A coalition of 156 countries has agreed on a “pioneering” agreement to enable rapid and equitable distribution of new coronavirus vaccines to 3% of the population of participating countries, to protect vulnerable health systems, frontline health workers and those in social institutions. The EU`s legal system is one of the least favorable for drug manufacturers when it comes to claims for compensation, although plaintiffs have rarely won, as the law requires them to prove the link between a disease and a vaccine that may have caused it. The health minister was in defense after Foreign Secretary Teodoro Locsin Jr posted an enigmatic tweet that an offer from the latter, Philippine Ambassador to the United States Jose Manuel “Babe” Romualdez, and U.S. Secretary of State Mike Pompeo, had already blocked 10 million doses of the vaccine in January 2021, “but that someone had dropped the ball.” The deal with AstraZeneca was negotiated before halting late studies of its vaccine candidate this month, after a British volunteer developed neurological symptoms. Trials have resumed in Britain, but not in the United States. What was the factor of bureaucracy during the weeks it took the government to sign a CDA with Pfizer? Duque was evasive and said a new vaccine should give the government some “permission.” What shows Duque`s timeline is how a mix of bureaucracy, coupled with the uncertainty of a new vaccine, has hampered the process of negotiating a sales contract long before it can even begin.
According to the first results of clinical trials from the University of Oxford, the vaccine he is developing with AstraZeneca could be only 62 percent effective for a two-dose diet, compared to about 95 percent for Pfizer and Moderna. AstraZeneca has not completed its Phase 3 clinical trial in the U.S., in part because it has been delayed by safety concerns. The agreements reflect different strategies by two of the world`s leading drug manufacturers to protect themselves, while a debate rages over the binding nature of vaccines to end the pandemic. If an agreement were to be reached, it could remedy, at least in part, an impending shortage that the administration itself has likely co-ordered by no longer pre-ordering doses of the vaccine developed by Pfizer with its German partner BioNTech. Pfizer agreed this summer to supply 100 million doses to the United States by the end of March, enough to vaccinate 50 million people, its vaccine requiring two vaccinations. June 24, 2020 – Pfizer sends the Philippine government an overview of its vaccine development and production program. Responsibility has been a significant stumbling blocks in discussions with other COVID-19 vaccine makers, European officials said, as companies fear risking higher legal costs than they normally face when vaccines are developed in much longer studies. According to a person familiar with the situation, Pfizer asked suppliers for this privileged status months ago. But before it was clear which vaccine studies would be successful, Trump administration officials seemed worried about hindering other vaccine makers who had accepted billions of dollars in federal subsidies. Federal officials have worked to prioritize orders for production supplies from these companies, including Moderna. While Pfizer`s stake in Operation Warp Speed is in this regard different from that of other companies in the vaccine race, there`s no sense in treating the deal as a simple purchase by the government, says James Love, director of Knowledge Ecology International, a nonprofit public interest group that focuses on intellectual property. .